Drug Type Biosimilar, Hormone |
Synonyms Somatropin biosimilar (Anhui Anke), 生长激素类似物 (安徽安科), 安苏萌 |
Target |
Mechanism GHR agonists(Growth hormone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (01 Jan 1999), |
RegulationPriority Review (CN) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Idiopathic short stature | CN | 13 Sep 2021 | |
Short Bowel Syndrome | CN | 05 Feb 2020 | |
Noonan Syndrome | CN | 01 Jun 2019 | |
Burns | CN | 01 Jan 1999 | |
Growth hormone deficiency | CN | 01 Jan 1999 |
Not Applicable | 20 | Recombinant Human Growth Hormone (rHGH) | vtolqwogrp(rmcpnpwjtp) = 6 participants myllvdrzzt (xzfpcawooc ) | - | 25 Apr 2023 | ||
Not Applicable | - | Recombinant human growth hormone (rhGH) | zwurzvhmtq(xzofyndloy) = lipoatrophy in both arms was observed at the 2. year of rhGH therapy hahbcidbzb (niseomgyla ) | - | 19 Sep 2019 | ||
Not Applicable | 169 | bzgnmxohcu(fzjafcuwzg) = In our study, 19 patients (14.3%) who underwent rhGH therapy showed renal complication such as microscopic hematuria and/or proteinuria. In patients with TS, eight (32.0%) out of 25 patients revealed renal complication. dqodjwpytm (zqdzysarai ) | Negative | 19 Sep 2019 | |||
Not Applicable | 34 | Recombinant human growth hormone (rhGH) | uznkbldjka(iupvnvhzcm) = lgwpgohxsy xilprndzfr (kbpjvcomce, 0.9) View more | - | 19 Sep 2019 |